Personalized immune attack on deadly brain cancer
NCT ID NCT05341947
Summary
This early-stage study aimed to test the safety of a personalized immune therapy for people with recurrent glioblastoma, an aggressive brain cancer. Researchers planned to collect patients' own immune cells, modify them to target cancer stem cells, and reinfuse them. The main goal was to find the highest safe dose, while also checking if the treatment helped patients live longer or improved their quality of life. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
Conditions
Explore the condition pages connected to this study.